{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T22:53:24Z","timestamp":1783119204114,"version":"3.54.6"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Regarding clinically-concerning non-standard initial anti-tuberculous (TB) regimens, few studies have examined their prevalence, risk factors and impacts. We recruited patients with drug susceptible TB and non-standard initial anti-TB regimens (NSTB group) and matched them with patients with standard initial regimens (STB group) in a 1:1 ratio. The risk factors and outcomes were analyzed. During the 11-year study period, we analyzed 50 (3.7%) patients with NSTB from a total set of 1337 patients with drug-susceptible TB. Pyrazinamide (60%) was the drug most commonly not prescribed in the NSTB group, followed by ethambutol (34%). Multivariable logistic regression identified  independent risk factors as\u00a0underlying eye disease (adjusted odds ratio [aOR]: 8.869; 95% CI 2.542\u201330.949; p\u2009=\u20090.001), gout\/hyperuricemia (aOR: 4.012 [1.196\u201313.425]; p\u2009=\u20090.024), and liver disease (aOR: 12.790 [3.981\u201341.089]; p\u2009&lt;\u20090.001). The NSTB group had longer treatment durations (281\u2009\u00b1\u2009121 vs. 223\u2009\u00b1\u200963\u00a0days; p\u2009=\u20090.003) and more occurrences of treatment interruption (26% vs. 8%; p\u2009=\u20090.021) than the STB group. In conclusion,\u00a0NSTB occurs in around 3.7% of patients and is associated with longer treatment and more treatment interruption. The risk factors might include underlying liver and eye diseases, and gout. Further studies to improve non-standard initial regimens and prevent negative outcomes are warranted.<\/jats:p>","DOI":"10.1038\/s41598-024-55273-5","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T15:03:22Z","timestamp":1709823802000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The prevalence, clinical reasoning and impact of non-standard anti-tuberculosis regimens at the initial prescription"],"prefix":"10.1038","volume":"14","author":[{"given":"Rou-Tsern","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Yung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Chung","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang-Huei","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"key":"55273_CR1","unstructured":"World Health Organization. Global Tuberculosis Report 2023 (World Health Organization, 2023)."},{"key":"55273_CR2","unstructured":"World Health Organization. Global Tuberculosis Report 2021 (World Health Organization,  2021)."},{"key":"55273_CR3","unstructured":"World Health Organization Global Strategy and Targets for Tuberculosis Prevention, Care and Control After 2015: Report by the Secretariat. https:\/\/apps.who.int\/iris\/handle\/10665\/172828 (2014)."},{"issue":"9441","key":"55273_CR4","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/S0140-6736(04)17141-9","volume":"364","author":"A Jindani","year":"2004","unstructured":"Jindani, A., Nunn, A. J. & Enarson, D. A. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: International multicentre randomised trial. Lancet 364(9441), 1244\u20131251 (2004).","journal-title":"Lancet"},{"issue":"17","key":"55273_CR5","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa1407426","volume":"371","author":"SH Gillespie","year":"2014","unstructured":"Gillespie, S. H. et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N. Engl. J. Med. 371(17), 1577\u20131587 (2014).","journal-title":"N. Engl. J. Med."},{"key":"55273_CR6","unstructured":"Centers for Disease Control MoHaW, R.O.C. (Taiwan). Taiwan Guidelines for TB Diangosis and Treatment. 5th edn (Center for Disease Control, 2022)."},{"key":"55273_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab190","author":"R Subbaraman","year":"2021","unstructured":"Subbaraman, R. et al. Understanding nonadherence to tuberculosis medications in India using urine drug metabolite testing: A cohort study. Open Forum Infect. Dis. https:\/\/doi.org\/10.1093\/ofid\/ofab190 (2021).","journal-title":"Open Forum Infect. Dis."},{"issue":"7","key":"55273_CR8","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1093\/cid\/ciw376","volume":"63","author":"P Nahid","year":"2016","unstructured":"Nahid, P. et al. Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of drug-susceptible tuberculosis. Clin. Infect. Dis. 63(7), e147\u2013e195 (2016).","journal-title":"Clin. Infect. Dis."},{"issue":"2 Suppl 1","key":"55273_CR9","first-page":"S1","volume":"39","author":"F National Kidney","year":"2002","unstructured":"National Kidney, F. K\/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am. J. Kidney Dis. 39(2 Suppl 1), S1-266 (2002).","journal-title":"Am. J. Kidney Dis."},{"issue":"5","key":"55273_CR10","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1164\/rccm.200904-0549OC","volume":"180","author":"HH Lin","year":"2009","unstructured":"Lin, H. H., Ezzati, M., Chang, H. Y. & Murray, M. Association between tobacco smoking and active tuberculosis in Taiwan: Prospective cohort study. Am. J. Respir. Crit. Care Med. 180(5), 475\u2013480 (2009).","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"17","key":"55273_CR11","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1314210","volume":"371","author":"A Jindani","year":"2014","unstructured":"Jindani, A. et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N. Engl. J. Med. 371(17), 1599\u20131608 (2014).","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"55273_CR12","first-page":"878","volume":"14","author":"CY Chiang","year":"2010","unstructured":"Chiang, C. Y. et al. Inconsistent dosing of anti-tuberculosis drugs in Taipei, Taiwan. Int. J. Tuberc. Lung Dis. 14(7), 878\u2013883 (2010).","journal-title":"Int. J. Tuberc. Lung Dis."},{"issue":"8","key":"55273_CR13","doi-asserted-by":"publisher","first-page":"815","DOI":"10.3390\/v12080815","volume":"12","author":"CJ Liu","year":"2020","unstructured":"Liu, C. J. & Chen, P. J. Elimination of hepatitis B in highly endemic settings: Lessons learned in Taiwan and challenges ahead. Viruses 12(8), 815 (2020).","journal-title":"Viruses"},{"issue":"Suppl 3","key":"55273_CR14","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/BF02779290","volume":"26","author":"DS Chen","year":"1991","unstructured":"Chen, D. S., Wang, J. T., Chen, P. J., Wang, T. H. & Sung, J. L. Hepatitis C virus infection in Taiwan. Gastroenterol. Jpn. 26(Suppl 3), 164\u2013166 (1991).","journal-title":"Gastroenterol. Jpn."},{"issue":"5","key":"55273_CR15","first-page":"616","volume":"14","author":"JY Chien","year":"2010","unstructured":"Chien, J. Y. et al. Hepatitis C virus infection increases hepatitis risk during anti-tuberculosis treatment. Int. J. Tuberc. Lung Dis. 14(5), 616\u2013621 (2010).","journal-title":"Int. J. Tuberc. Lung Dis."},{"issue":"6","key":"55273_CR16","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jinf.2011.04.005","volume":"62","author":"JY Wang","year":"2011","unstructured":"Wang, J. Y. et al. Risk factors of hepatitis during anti-tuberculous treatment and implications of hepatitis virus load. J. Infect. 62(6), 448\u2013455 (2011).","journal-title":"J. Infect."},{"issue":"8","key":"55273_CR17","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1124\/dmd.121.000389","volume":"49","author":"Z Hussain","year":"2021","unstructured":"Hussain, Z., Zhu, J. & Ma, X. Metabolism and hepatotoxicity of pyrazinamide, an antituberculosis drug. Drug Metab. Dispos. 49(8), 679\u2013682 (2021).","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"55273_CR18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/0041-3879(85)90040-6","volume":"66","author":"DA Mitchison","year":"1985","unstructured":"Mitchison, D. A. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 66(3), 219\u2013225 (1985).","journal-title":"Tubercle"},{"issue":"3","key":"55273_CR19","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1378\/chest.06-2042","volume":"131","author":"YS Kwon","year":"2007","unstructured":"Kwon, Y. S. et al. Hepatitis C virus infection and hepatotoxicity during antituberculosis chemotherapy. Chest 131(3), 803\u2013808 (2007).","journal-title":"Chest"},{"issue":"3","key":"55273_CR20","doi-asserted-by":"publisher","first-page":"347","DOI":"10.5588\/ijtld.13.0545","volume":"18","author":"HJ Shin","year":"2014","unstructured":"Shin, H. J. et al. Hepatotoxicity of anti-tuberculosis chemotherapy in patients with liver cirrhosis. Int. J. Tuberc. Lung Dis. 18(3), 347\u2013351 (2014).","journal-title":"Int. J. Tuberc. Lung Dis."},{"issue":"10","key":"55273_CR21","first-page":"695","volume":"39","author":"AQ Pham","year":"2014","unstructured":"Pham, A. Q., Doan, A. & Andersen, M. Pyrazinamide-induced hyperuricemia. Pharm. Ther. 39(10), 695\u2013715 (2014).","journal-title":"Pharm. Ther."},{"issue":"7","key":"55273_CR22","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1136\/bjophthalmol-2020-316897","volume":"105","author":"S Mandal","year":"2021","unstructured":"Mandal, S. et al. Prospective study to evaluate incidence and indicators for early detection of ethambutol toxicity. Br. J. Ophthalmol. 105(7), 1024\u20131028 (2021).","journal-title":"Br. J. Ophthalmol."},{"issue":"2","key":"55273_CR23","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1164\/rccm.200407-863OC","volume":"172","author":"DE Griffith","year":"2005","unstructured":"Griffith, D. E. et al. Ethambutol ocular toxicity in treatment regimens for Mycobacterium Avium complex lung disease. Am. J. Respir. Crit. Care Med. 172(2), 250\u2013253 (2005).","journal-title":"Am. J. Respir. Crit. Care Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-55273-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-55273-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-55273-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,10]],"date-time":"2024-03-10T18:06:17Z","timestamp":1710093977000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-55273-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["55273"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-55273-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,7]]},"assertion":[{"value":"2 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5631"}}